Bayer Secures EYLEA EU Approval
News : German drugmaker Bayer has secured approval for a new indication of the EYLEA clinical property in the European market, the company confirmed in a press release. The solution was developed as a means to treat patients suffering from visual impairment due to macular edema resulting from central retinal vein occlusion . The company ' s regulatory submission of the drug was supported by positive data generated by two P hase III clinical studies.
BMI View: As with other markets in Western Europe, high-value, innovative medicines account for the majority of Germany's pharmaceutical market, with patented drugs comprising 66.8% of the total market's value of EUR38.89bn (US$49.39bn) in 2012. Generic drugs accounted for 21.2% of the market, with over-the-counter (OTC) medicines accounting for the remaining 12.0%.